Free Access
| Issue |
J Extra Corpor Technol
Volume 48, Number 1, March 2016
|
|
|---|---|---|
| Page(s) | 39 - 42 | |
| DOI | https://doi.org/10.1051/ject/201648039 | |
| Published online | 15 March 2016 | |
- Argueta-Morales IR, Olsen MC, DeCampli WM, Munro HM, Felix DE. Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2012;44:69–74. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Federman M, Dragomer D, Grant S, Reemtsen B, Biniwale R. Use of bivalirudin for anticoagulation during implantation of total artificial heart. J Extra Corpor Technol. 2014;46:170–2. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Garland C, Somogyi D. Successful implantation of a left ventricular assist device in a patient with heparin-induced thrombocytopenia and thrombosis. J Extra Corpor Technol. 2014;46:162–5. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Gates R, Yost P, Parker B. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs. 2010;34:667–9. [PubMed] [Google Scholar]
- Almond CSD, Harrington J, Thiagarajan R, et al. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant. 2006;25:1376–9. [CrossRef] [PubMed] [Google Scholar]
- Zhang D, Wang Z, Zhao X, Lu W, Gu J, Cui Y. Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects. Biol Pharm Bull. 2011;34:1841–8. [CrossRef] [PubMed] [Google Scholar]
- DiNisio M, Middledorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40. [CrossRef] [PubMed] [Google Scholar]
- Jones PM, Bainbridge D, Dobkowski W, et al. Comparison of MAX-ACT and K-ACT values when using bivalirudin anticoagulation during minimally invasive hybrid off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011;25:415–8. [CrossRef] [Google Scholar]
- Wasowicz M, Vegas A, Borger M, Harwood S. Bivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Can J Anaesth. 2005;52:1093–8. [CrossRef] [PubMed] [Google Scholar]
- Morshuis M, Boergermann J, Gummert J, Koster A. A modified technique for implantation of the HeartWare™ left ventricular assist device when using bivalirudin anticoagulation in patients with acute heparin-induced thrombocytopenia. Interact Cardiovasc Thorac Surg. 2013;17:225–6. [CrossRef] [PubMed] [Google Scholar]
- Matte GS. Perfusion for Congenital Heart Surgery: Notes on Cardiopulmonary Bypass for a Complex Patient Population. Hoboken, NJ: Wiley-Blackwell; 2015:159. [Google Scholar]
- Koster A, Chew D, Grundel M, et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: An in vitro study. Anesth Analg. 2003;96:1316–9. [CrossRef] [PubMed] [Google Scholar]
- Koster A, Buz S, Krabatsch T, et al. Effect of modified ultrafiltraion on bivalirudin elimination and postoperative blood loss after on-pump coronary bypass grafting: An assessment of different filtration strategies. J Card Surg. 2008;23:655–8. [CrossRef] [PubMed] [Google Scholar]
- Stratmann G, deSilva Am, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004;98:1635–9. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.